RxDoctor Payments Data

Amanda Ellis, APRN

Family · Cuyahoga Falls, OHNPI 1902443195

Payments from drug & device makers

$2,002in general payments, 2019–2025

Across 120 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$290
  • AstraZeneca$201
  • Biohaven Pharmaceutical Holding Company Ltd.$158
  • Sunovion Pharmaceuticals Inc.$138
  • GSK$108
  • Teva Pharmaceuticals USA, Inc.$107
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$1,98799%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,002 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$704
Medicare patients
44
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin203$220,796
TrulicityDulaglutide74$80,972
FarxigaDapagliflozin Propanediol100$71,708
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$53,826
EliquisApixaban50$50,515
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$50,392
SymbicortBudesonide/Formoterol Fumarate65$24,782
RybelsusSemaglutide15$24,565
Breo ElliptaFluticasone/Vilanterol42$22,725
SynjardyEmpagliflozin/Metformin Hcl21$18,279
Albuterol Sulfate HfaAlbuterol Sulfate367$13,862
VascepaIcosapent Ethyl17$8,728
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$7,223
LinzessLinaclotide12$6,599
Omeprazole364$5,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$75$239,075224 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$201$150,316224 claims
Lilly USA, LLCTrulicity$74$80,97274 claims
GSKTrelegy Ellipta, Breo Ellipta$108$73,11783 claims
PfizerEliquis$14$50,51550 claims
Novo NordiskRybelsus$74$24,56515 claims
AbbVieLinzess$290$6,59912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Cuyahoga Falls

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →